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Abstract 
We report the athletic, physiological and mitochondrial-related genomic data of an 
Israeli endurance runner. He is holding the Israeli record in 10000, 5000, 1500 and 
800m run, along with being one of the best Israeli 400m runners. We tested the 
ACTN3 R577X, and six polymorphisms in the PPARGC1A-NRF-TFAM  pathway 
genes. The case athlete was heterozygous for the ACTN3 R577X variation and had 
five out of six ‘endurance-oriented’ genotypes, scoring significantly high in 
endurance ‘optimal’ genotype profile. In conclusion, we suggest that the case athlete 
is favoured by polygenic profile that is more suitable for mitochondrial biogenesis, 
regardless of his good phenotypic accomplishments in short-term running events. 
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1. Introduction 
Elite athletic performance is a complex phenotype influenced by both environmental 
and genetic factors. Up to date the bulk of research indicates that the effect of a single 
gene variant on elite athletic status is rather small (Rankinen et al. 2010), and 
attaining elite status probably involves multiple genetic factors. To date, over 20 
single nucleotide polymorphisms (SNPs) have been found to be individually 
associated with elite athletic status, ranging from endurance to sprint/power-oriented 
events (Ostrander et al. 2009). Among them are muscle-specific SNPs  namely; the 
R577X substitution in the α-actinin-3 (ACTN3) gene (Druzhevskaya et al. 2008; 
Eynon et al. 2009e; Niemi and Majamaa, 2005; Yang et al. 2003), and the A/G SNP 
in the muscle-specific creatine kinase (CK-MM Ncol) gene ( Santiago et al. 2010). 
However, it is still unknown whether different genetic variations and combinations 
play a role in specific athletic area (i.e. endurance performance or power-oriented 
performance) (Ruiz et al. 2009). 
Metabolic phenotypes are essentially different between endurance and 
sprint/power athletic performance. Elite endurance performance requires enhanced 
oxidative capacity achieved by increasing several components of the mitochondrial 
respiratory chain (Mole et al. 1971) thus, resulting in high-levels of maximal oxygen 
consumption (VO2max). VO2max is arguably limited by cardiac output at least as 
much as it is by the capacity of skeletal muscle for oxidative phosphorylation. The 
muscle phenotype of endurance athletes is mainly composed of type I muscle fibers 
with a high mitochondrial density and size, which enables them to rely mainly on 
mitochondrial oxidation of carbohydrates and lipids for energy production . In 
contrast, short distance sprint and power performances are known to depend on 
anaerobic pathways which are especially dependent on intramuscular stored creatine 
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phosphate (CP), adenosine triphosphate (ATP), and glucose (Spencer and Gastin 
2001). Consequently, it is unusual to identify athletes who excel in short sprints as 
well as in long distance running. This theory was well supported by Van Damme and 
colleagues, who demonstrated that in world-class decathletes results in explosive 
power events such as the 100-m sprint or the long jump, are negatively correlated 
with endurance-oriented event such as the 1,500-m race (Van Damme et al. 2002). 
Given the aforementioned phenotype differences between endurance and sprint/power 
athletes, it is presumed that the ‘optimum’ genotype profile also differs between these 
two types of athletes.  
Evidence from both human (Mahoney et al. 2005; Norrbom et al. 2004; 
Russell et al. 2003; Short et al. 2003) and animal studies (Baar et al. 2002; Terada et 
al. 2002) imply that transcription factors and co-activators in the peroxisome 
proliferator-activated receptor (PPAR)-nuclear respiratory factor (NRF)- 
mitochondrial transcription Factor A (TFAM) pathway influence endurance 
performance, due to their key role in regulation of cellular energy metabolism. 
Previous studies from our laboratory indicated  that the R577X substitution in the 
ACTN3 gene (Eynon et al. 2009e) and several variants in the PPARGC1A-NRF-TFAM 
pathway (Eynon et al. 2009a; 2009b; 2009c; 2009d; ) are associated with elite athletic 
status. We also suggested that in general, endurance athletes have a polygenic profile 
that is more adjusted for mitochondrial biogenesis, as opposed to power athletes or 
non-athletic controls (Eynon et al. 2010).  
  Here we report the specific physiological variables and the mitochondrial-
related genomic predisposition of a track athlete who successfully competes in both 
short and long running distances that are considered to represent two physiological 
end-points of the human performance continuum. 
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2. Case Report 
We studied an Israeli endurance runner (age=36 years, height=180 cm, weight=65 kg, 
body fat percentage=8%) whose main event is the 10000m race. He is holding the 
Israeli record in 10,000, 5000, 3000, 1500 and 800m running events, but also 
routinely run the 400m race at national and international track and field meets. His 
personal best running times are reported in Table 1. We genotyped six genetic SNPs 
in the PPARGC1A-NRF-TFAM  pathway genes, which are known to be associated 
with endurance exercise performance capacity: (i) NRF2 A/C (rs12594956) (Eynon et 
al. 2009a); (ii) NRF2 A/G (rs7181866) (Eynon et al. 2009d; He et al. 2008); (iii) 
NRF2 C/T (rs8031031) (Eynon et al. 2009a); (iv) peroxisome proliferator-activated 
receptor alpha (PPARA) intron 7 G/C (rs4253778) (Ahmetov et al. 2006; Eynon et al. 
2009b); (v) peroxisome proliferator-activated delta (PPARD) C294T (Eynon et al. 
2009c); (Skogsberg et al. 2003); and (vi) PPARGC1A Gly482Ser (Eynon et al. 2009c; 
Lucia et al. 2005). We also studied the ACTN3 R577X polymorphism, which is 
known to be associated with power-oriented performance (Druzhevskaya et al. 2008; 
Eynon et al. 2009e; Niemi and Majamaa, 2005; Yang et al. 2003). The studied 
polymorphisms and genotypes of the Israeli endurance runner are presented in Table 
2.  
2.1 Graded exercise tests 
The subject came to the laboratory twice in order to perform two different tests. 
During the first session an incremental maximal running test was carried out on a 
motor-driven treadmill (Woodway, Germany), in order to determine his maximal 
oxygen uptake (VO2 max). The initial speed was 13 km/h and the grade was 1%. 
Speed was increased by 1 km/h every minute while grade was maintained at 1% until 
the fifth stage (5th min). From this point on, inclination was increased by 2% every 
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minute while speed was kept constant until volitional exhaustion. Expired gases and 
respiratory exchange ratio (RER) were measured breath by breath throughout the test, 
using an automated on-line metabolic analysis system (SensorMedics Vmax 29, 
USA).  
In the second session, the lactate threshold (LT) was determined by 
monitoring blood lactate concentration during a graded running test. Initial running 
velocity was 14 km/h and increased by 1 km/h every 4 minutes. A capillary blood 
sample was collected from a preheated fingertip at the end of each stage and analyzed 
using a portable lactate analyzer (Accusport, Boehringer Mannehein, Germany). 
Lactate concentration values were plotted against running velocity and the LT  was 
determined at the point at which inflexion of the lactate curve occurred.  
During both tests heart rate was recorded at each stage using a Polar heart rate 
monitor (Polar Accurex Plus, Polar Electro, Woodbury, NY). Rate of perceived 
exertion (RPE) was determined using the original 6-20 Borg scale at the end of each 
stage.   
2.2    Genotyping  
Genomic DNA was extracted from peripheral EDTA treated anti-coagulated blood 
using a standard protocol. Genotype analyses were performed using the polymerase 
chain reaction (PCR) following restriction fragment length polymorphism (RFLP) 
analysis as previously described (Eynon et al. 2009a; 2009b; 2009c; 2009d; 2009e ). 
To ensure proper internal control, for each genotype analysis we used known positive 
and negative controls from previously genotyped samples. The results were scored by 
two experienced and independent investigators who were blind to subject data. 
The study was approved by the Helsinki Committee, the formal ethics committee of 
the Hillel Yaffe Medical Center, Hadera, Israel, according to the Helsinki Declaration. 
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Written informed consent was obtained from the participant. The athlete consented to 
being identified in this way, and thus publicizing his genetic and other data. 
 
3. Results 
3.1 Physiological variables  
The athlete completed the exercise test without any complication. He exercised to 
exhaustion and stopped when he reached maximal effort and fatigue as evidenced by 
perceived exertion (RPE 19-20). His VO2max (which corresponded to a speed of 20.3 
km/h) was 80.4 ml·kg-1·min-1, while criteria of maximal effort attainment were met 
(maximal value of HR of 187 beats/min, blood lactate concentration at end-exercise 
of 11 mmol/L, and respiratory exchange ratio > 1.1) (Lucia et al. 2006). The running 
speed eliciting the LT was 19 km/h. 
3.2  ACTN3 and mitochondrial biogenesis-related genotypes  
The case athlete had five out of six "optimal" endurance (related to mitochondrial 
biogenesis) genotypes (Table 2), (Eynon et al.2010) and was heterozygous for the 
ACTN3 R577X genotype (i.e.; harboured the RX genotype). It is also noteworthy that 
none of the other endurance athletes we previously studied had an ‘optimal’ (six out 
of six) endurance genotype profile, i.e. theoretically most favourable for 
mitochondrial biogenesis (Eynon et al. 2010). Taken together the present data and 
those we recently published (Eynon et al. 2010), it seems that the probability of 
occurrence of the theoretically optimum genotype profile is very rare, at least in terms 
of mitochondrial-related genes. The comparison between the endurance "optimal" 
genotype and the "power-oriented" genotypes is presented in Table 2. 
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4. Discussion 
We examined the endurance polygenic profile of six polymorphisms  in the PPAR-
NRF-TFAM genes pathway, and the R577X variation in  the ACTN3 gene, as well as 
physiological variables of an endurance runner who excel in short as well as in long 
distance running. Our main finding was that the subject has a theoretically 
mitochondrial-related genotype that is more suitable for endurance-type events. This 
finding is unexpected due to his ability to outperform also in a short and mid-term 
running events, i.e. 400m and 800m , which probably are  different from longer events 
both in physiological and genotype profiles.  
The most extensively studied genetic polymorphism by far; in the context of 
power-oriented athletic performance is the ACTN3 R577X. It has been demonstrated 
that the RR genotype is over-represented in several groups of power-athletes 
(Druzhevskaya et al. 2008; Eynon et al. 2009e; Niemi and Majamaa, 2005; Yang et al. 
2003), with the overall conclusion that this specific genotype may confer an 
advantage in power-oriented sports events, e.g. sprint, jumping or throwing. This 
observation, along with the notion that the case-athlete was heterozygous for this 
polymorphism , leads to believe that, at least in terms of this specific SNP, the athlete 
does not have the most suitable genotype for becoming an elite-level sprinter.    
Although the athletes' VO2max approached the highest reported values for 
humans, representing a high potential for endurance performance, he held also the 
national record in 800m, and was also positioned among the best 400m runners in 
Israel. This phenomenon is very uncommon among runners, but not so uncommon in 
swimming. This can be seen from the records of top world class-swimmers, such as 
Ian Thorpe (world record holder in 100-m relay, and individual 200, 400, and 800-m 
swims), and Grant Hackett (world record holder in 200-m relay, and individual 400, 
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800, and 1500-m swims), as well as others who excel in both short and long 
swimming distances. This may be at least partially explained by the usual emphasis 
put on high volume training loads by swimming coaches , regardless of the swimmer's 
event specialty.  
Elite athletes represent a somewhat unique model of study. These individuals 
have undergone extreme physiological adaptations (e.g. in muscle oxidative capacity, 
as a result of increased mitochondrial content) that are likely to be the consequence of 
years of training as well as of the interaction between exercise training and a 
favorable polygenic profile (Ruiz et al. 2009). In the present study, our case athlete 
represents even more "exceptional" model by holding the all times Israeli national 
records in 10,000m and 800 m running events,  and by being one of the best Israeli 
400m runners. 
A continuous near-maximal (>90% VO2max), and a supra-maximal efforts are 
required in 10,000 m and 400m track events respectively (Rubio et al. 2005). In the 
performance of both types of running events a highly adapted glycolysis metabolic 
pathway at the muscle level might explain the aforementioned phenomenon.  
One limitation of this report lies on the fact that the case-athlete belongs to a 
very unique minority group of Ethiopian Jews.  Between the years 1977-1991, 27000 
Ethiopian Jews immigrated to Israel. During the last 34 years their only influence on 
the Israeli track & field record table was in the half marathon and marathon run, and 
none belonged to the top ten all times ranking in 800m, 1500m and 3000m running 
events. Moreover, in recent years, we collected DNA samples from eight long-
distance Ethiopian Jews runners and found that their genotype profile was similar to 
that of native Israeli long-distance runners (unpublished data).  
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We are also aware that compared to the world record list, the athlete's results 
are not so impressing. However, the case-athlete is very unique in his own country, 
and we are not aware of any other country in the world in which the national record 
holder in 800m through 10000m run is the same person, and the same athlete is also 
ranked at the top four of the nation's all times results in the half marathon run. 
In conclusion, we suggest that the case athlete is, in general, favoured by a 
physiological profile and polygenic endowment that are more suitable for 
mitochondrial biogenesis, which could apply also for his good result in 400m and 
800m run. This case study represents a model of how evaluation of the polygenic 
profile can assist athletes and their coaches in the preparation of a training program 
and in track specialty selection. It is well known that aerobic and anaerobic specificity 
develops toward the end of puberty (Bar-or & Rowland, 2004), and that during early 
puberty athletes may excel in both short and long distance events. Thus, early 
information regarding the polygenetic profile can direct the athlete and his/her coach 
towards the sports event for which he is best suited (e.g. aerobic versus anaerobic). 
However, it is still premature and speculative to predict the possibility of one 
becoming an endurance or sprint/power athletic champion based on genetic data.   
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Table 2. Studied polymorphisms and genotype of the case study athlete (Israeli 
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